NCT04061863Unknown1 期
A Phase IB/II, Single Arm, Multi-center Study of Nivolumab in Combination With Eribulin in HER2 Negative Metastatic Breast Cancer Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- 6 months progression-free survival (PFS) rate
研究概览
简要总结
Cancer therapeutics such as chemotherapy may modulate tumor/immune-system interactions in favor of the immune system. Chemotherapy can result in tumor cell death with a resultant increase in tumor antigen delivery to antigen-presenting cells. Therefore, combining immunotherapy (Nivolumab) with chemotherapy (Eribulin) is a promising anti-cancer strategy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Provision of informed consent prior to any study specific procedures
- •Age 20 years or older
- •ECOG performance status(PS) 0 or 1
- •Histologically confirmed stage IV or recurrent breast cancer
- •HER2 negative disease: not eligible for anti-HER2 therapy
- •* HER2 negative [IHC 0, 1+ or IHC 2+ with corresponding ISH non-amplified or ratio less than 2.0 or ISH non-amplified ratio less than 2.0] as per ASCO-CAP HER2 guideline recommendations 2013 (ASCO-CAP)
- •Patients previously treated with anthracycline and/or taxane unless contraindicated; Patients who received anthracycline and/or taxane based chemotherapy in either the neoadjuvant, adjuvant or metastatic setting and experienced disease progression on or after taxane-based chemotherapy in the metastatic setting
- •No more than 3 prior lines of cytotoxic chemotherapy for metastatic disease; patients who experienced disease recurrence within 1 year after completion of (neo)adjuvant anthracycline and taxane-based chemotherapy will be counted as 1 prior line of treatment.; hormonal therapy will not be counted as a prior line of treatment
- •Measurable disease according to RECIST v 1.1.
排除标准
- •Previous treatment with eribulin mesylate or any anti-PD-1, PD-L1, or PD-L2
- •Active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc) is not considered a form of systemic treatment.
- •Known central nervous system (CNS) disease, except for those subjects with treated brain metastasis who are stable for at least 1 month, having no evidence of progression or hemorrhage after treatment and no ongoing requirement for corticosteroids, as ascertained by clinical examination and brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT]) during the screening period
- •Known history of human immunodeficiency virus (HIV) positive
- •Known active hepatitis B or hepatitis C (eg, HCV RNA detected)
- •Any other malignancy that required treatment or has shown evidence of recurrence (except for nonmelanoma skin cancer, or histologically confirmed complete excision of carcinoma in situ) during the 3 years prior to enrollment in this study
- •History of significant cardiovascular disease
- •Hypersensitivity to the active substance or any other excipients of the eribulin mesylate drug product, or to nivolumab
- •Scheduled for major surgery during the study
- •Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. The use of physiologic doses of corticosteroids may be allowed
- •Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
- •Has a history of interstitial lung disease
- •Has received a live-virus vaccination within 30 days of planned start of study therapy. Seasonal flu vaccines that do not contain live virus are permitted.
研究组 & 干预措施
ER+/HER2- breast cancer
Experimental
will be treated with a combination of eribulin and nivolumab
干预措施: Nivolumab (Drug)
ER-/HER2- breast cancer
Experimental
will be treated with a combination of eribulin and nivolumab
干预措施: Nivolumab (Drug)
结局指标
主要结局
6 months progression-free survival (PFS) rate
时间窗: 6 months
次要结局
- Incidence Rate of each Toxicity by CTCAE 4.0(2 years (upto 5 years))
- Clinical benefit rate by RECIST criteria v 1.1 (and iRECIST)(2 years)
- Objective response rate by RECIST criteria v 1.1(2 years)
- Overall survival (OS)(2 years (upto 5 years))
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had ChemotherapyBreast CancerColon CancerBladder CancerNCT01339000National Cancer Institute (NCI)1
终止
2 期
Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).Fallopian Tube CancerPeritoneum CancerEpithelial Ovarian CancerNCT02834975University of Miami26
已完成
1 期
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)Prostate CancerNCT03493945National Cancer Institute (NCI)59
已完成
2 期
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous LeukemiaLeukemiaNCT00005962Eastern Cooperative Oncology Group
终止
2 期
Accelerated Checkpoint Therapy for Any Steroid Dependent Patient With Brain MetastasesBrain Metastases, AdultNCT04461418AHS Cancer Control Alberta2